Observational analysis shows the balance of ischemic and bleeding risks in NSTEMI patients, suggesting precision medicine may enhance patient care.
Key Points
Dual antiplatelet therapy significantly reduces recurrent myocardial infarction and stent thrombosis, while also posing risk for major bleeding complications.
A careful balance between preventing ischemic events and minimizing bleeding risks is essential for effective NSTEMI management.
Implementation of precision medicine allows treatment tailoring based on individual patient data, enhancing overall outcomes.
The approach aims to provide optimal therapy for NSTEMI patients, highlighting the complexity of dual antiplatelet therapy.